| NCT06429800 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus | WITHDRAWN | PHASE1 | 2025-04-16 | 2025-04-16 | 2025-04-16 |
| NCT06256484 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | TERMINATED | PHASE1 | 2024-09-06 | 2025-03-30 | 2025-03-03 |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | TERMINATED | PHASE1, PHASE2 | 2019-02-19 | 2021-08-19 | 2021-08-19 |
| NCT03283826 | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis | TERMINATED | PHASE1, PHASE2 | 2017-10-19 | 2024-01-17 | 2023-11-09 |
| NCT01498484 | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies | COMPLETED | PHASE2 | 2011-12 | 2019-07 | 2019-07 |
| NCT00002663 | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | COMPLETED | PHASE1, PHASE2 | 1995-03 | 2019-07 | 2019-07 |